Key Stats for Humana Stock
- Past-Week Performance: +0.4%
- 52-Week Range: $169.6 to $315.6
- Current Price: $187.3
What Happened?
Humana‘s March 2 guidance reaffirmation of at least $9.00 adjusted EPS landed while HUM trades at $187.28, sitting 40.6% below its 52-week high, exposing a market still pricing in structural MA collapse rather than a recovery.
On February 25, CenterWell President Sanjay K. Shetty purchased Humana common shares on the open market, signaling insider conviction at current prices just days before the March 2 SEC filing confirmed full-year guidance unchanged.
Beneath the EPS headline, Humana’s individual MA membership is growing 25% in 2026 while management targets a doubling of individual MA pre-tax margin normalized for the $3.5 billion Stars headwind already embedded in guidance.
CEO James Rechtin stated on the Q4 earnings call that “we must deliver a stable and compelling margin,” a commitment now backed by Aaron Martin’s January appointment as President of Medicare Advantage ahead of the March 10 Leerink conference appearance.
The market is treating Humana’s Stars headwind as a permanent discount, yet management’s $1.6 to $2.0 billion transformation savings target and top-quartile Stars trajectory by BY 2028 position the company for a fundamental re-rating within three years.
Wall Street’s Take on HUM Stock
Humana’s March 2 guidance reaffirmation directly confirms that the $3.5 billion Stars headwind is already fully priced into the $9.00 adjusted EPS floor, removing the biggest overhang threatening the 2026 earnings trajectory.
Yet the fundamental picture shows compression before recovery, with 2026 EPS estimated at $9.66 against FY 2025’s $17.14, while forward revenue accelerates to $158.36 billion at 22.1% growth, signaling volume strength masking a margin trough.
Wall Street currently shows 6 buys, 2 outperforms, 17 holds, and 2 sells against a mean price target of $223.88, implying 19.5% upside from $187.28, with conviction notably thin as analysts wait for Stars recovery evidence.
The target range spans $146 on the low end to $344 on the high, where the downside reflects a failed 2028 Stars recovery and the upside hinges on Humana hitting top-quartile ratings and doubling individual MA margins as guided.
What Does the Valuation Model Say?
The TIKR mid-case model sets a target of $693.71, implying 270.4% total return over 4.8 years at a 31.1% annualized IRR from today’s price.
That gap between $187.28 and $693.71 is not a rounding error; it reflects a market pricing permanent impairment into a business with a confirmed 25% membership growth year.
The mispricing becomes undeniable when revenue is growing 22.1% in 2026 yet the stock sits 40.6% below its 52-week high of $315.35.
CenterWell President Sanjay K. Shetty’s open-market share purchase on February 25 tells you insiders do not share the market’s structural pessimism at these levels.
However, if the final Medicare Advantage rate notice lands materially below medical cost trend and forces benefit cuts beyond what the $9.00 EPS floor already assumes, the 2028 margin recovery thesis collapses entirely.
The March 10 Leerink Partners Global Healthcare Conference presentation by CEO Jim Rechtin and CFO Celeste Mellet will serve as the first post-reaffirmation signal of whether management upgrades its tone on Stars recovery and 2028 earnings power.
HUM is deeply undervalued at $187.28 given a 270.4% model upside, but the re-rating requires March 10 conference commentary to confirm the 2028 earnings unlock is still firmly on track.
Should You Invest in Humana, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up HUM stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Humana, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HUM stock on TIKR for Free →
